Growth Hormone Deficiency and Growth Hormone Replacement in Childhood Cancer Survivors.

2区医学 Q2 Medicine

Frontiers of Hormone Research Pub Date : 2021-01-01 Epub Date: 2021-04-30 DOI:10.1159/000515111

Briana C Patterson, Lillian R Meacham

引用次数: 1

Abstract

Growth hormone deficiency (GHD) is common in childhood cancer survivors (CCS). Major risk factors for GHD include radiation therapy, both cranial and total body irradiation, and tumor location. Some newer anti-cancer therapies may impact growth and the GH-IGF-1 axis as well. While untreated childhood-onset GHD adversely impacts adult height in CCS, longstanding GHD can cause or exacerbate multiple metabolic and skeletal health problems. This chapter discusses considerations in the diagnosis and treatment of GHD in CCS and discusses long-term outcomes in survivors of childhood cancer who have GHD.

查看原文本刊更多论文

儿童癌症幸存者的生长激素缺乏和生长激素替代。

生长激素缺乏症(GHD)在儿童癌症幸存者(CCS)中很常见。GHD的主要危险因素包括放射治疗，包括头部和全身照射，以及肿瘤的位置。一些新的抗癌疗法也可能影响生长和GH-IGF-1轴。虽然儿童期发病的GHD未经治疗会对CCS患者的成年身高产生不利影响，但长期的GHD会导致或加剧多种代谢和骨骼健康问题。本章讨论了CCS中GHD诊断和治疗的注意事项，并讨论了患有GHD的儿童癌症幸存者的长期预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Frontiers of Hormone Research 医学-内分泌学与代谢

自引率

0.00%

发文量

期刊介绍： A series of integrated overviews on cutting-edge topics New sophisticated technologies and methodological approaches in diagnostics and therapeutics have led to significant improvements in identifying and characterizing an increasing number of medical conditions, which is particularly true for all aspects of endocrine and metabolic dysfunctions. Novel insights in endocrine physiology and pathophysiology allow for new perspectives in clinical management and thus lead to the development of molecular, personalized treatments. In view of this, the active interplay between basic scientists and clinicians has become fundamental, both to provide patients with the most appropriate care and to advance future research.